← The Wire
RGNXNasdaq
REGENXBIO Inc.
Biological Products, (No Diagnostic Substances) · CIK 1590877
Develops gene therapy treatments using its NAV Technology Platform for genetic defects and therapeutic protein production
⚡ Elevated coverage
$344M
Market cap
$11.83
Last close
+12.9%
1D
+30.4%
5D
2.5M
Volume
Price · last 39 sessions+26.0%
May 4L $5.65 · H $11.83Jun 29
215
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
SC 13GSC 13GNov 17, 2023SC 13GSC 13GApr 7, 2023SC 13GFILING REGENXBIO INC.Jan 15, 2021SC 13GSC 13GMar 6, 2020SC 13GSCHEDULE 13GFeb 14, 2020SC 13GSC 13GFeb 14, 2020SC 13GSC 13GFeb 13, 2020SC 13GREGENXBIO INC.Feb 13, 2019SC 13GSC 13GFeb 12, 2019SC 13GSC 13GOct 5, 2017SC 13GSC 13GJan 30, 2017SC 13GREGENXBIO SCHEDULE 13G 2-11-16Feb 16, 2016SC 13GSC 13GSep 25, 2015SC 13GFMR 13GSep 25, 2015SC 13GBROOKSIDE 13G REGENXBIO AS OF 9/24/2015Sep 24, 2015SC 13GSC 13GSep 22, 2015
Insider Activity
In the 90 days to Mar 10, 2026: 1 sold $53K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 10, 2026 | Pakola SteveChief Medical Officer | Sell | 5,124 | $10.35 | $53K |
| Oct 9, 2025 | Simpson CurranChief Executive Officer | Sell | 20,811 | $12.62 | $263K |
| Sep 29, 2025 | Simpson CurranChief Executive Officer | Sell | 7,624 | $10.03 | $76K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance